Mesoblast (NASDAQ:MESO; ASX:MSB) submitted its completed biologics license application (BLA) to the FDA for Ryoncil, its lead allogeneic cell therapy for the treatment of children with steroid-refractory acute graft...
CytoDyn (OTCQB:CYDY) reported positive results from its Phase 1b/2 trial of leronlimab in patients with metastatic triple-negative breast cancer (mTNBC) and metastatic breast cancer (MBC). Data from the first patient...
Allergan (NYSE:AGN) expanded its partnership with closely-held Histogen to include exclusive rights to incorporate and commercialize Histogen’s cell conditioned media (CCM) in microdermabrasion therapies along...
Aprea Therapeutics (NASDAQ:APRE) received FDA breakthrough designation for APR-246, in combination with azacytidine, for the treatment of myelodysplastic syndromes (MDS) with a susceptible tumor suppressor protein p53...
Pulmatrix (NASDAQ:PULM) received FDA fast track designation for Pulmazole, an inhaled itraconazole antifungal for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. The safety...
The FDA cleared VistaGen Therapeutics’ (NASDAQ:VTGN) IND for AV-101 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease, enabling the company to proceed with Phase 2...
Bee Vectoring Technologies (BVT) International (TSXV:BEE; OTCQB:BEVVF) closed five new deals with blueberry growers in Florida, North Carolina and South Carolina to use its bee delivery system, VECTORITE with CR-7, on...
Hepion Pharmaceuticals (NASDAQ:HEPA) reported that its non-alcoholic steatohepatitis (NASH) candidate, CRV431, demonstrated superior antifibrotic efficacy in an expanded human liver study. The study design and its...
HLS Therapeutics (TSX:HLS) reported that its cardiovascular drug, Vascepa, will be available in Canada on or about February 18, 2020. Vascepa was approved by Health Canada at the end of 2019. HLS noted that the approval...
Akcea Therapeutics (NASDAQ:AKCA) reported positive topline results from its Phase 2 study of AKCEA-ANGPTL3-LRx in patients with hypertriglyceridemia, Type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD). ...